Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors from the central nervous method, conolidine modulates alternate molecular targets. A Science Improvements analyze uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By in... https://erichd729hvg8.vblogetin.com/profile